Amira Pharmaceuticals

Belkins
Amira Pharmaceuticals is a small molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory disease. Our discovery team is building on unparalleled insights into bioactive lipid pathways and complex signaling processes controlling many conditions including asthma, chronic obstructive pulmonary disease, cardiovascular and fibrotic diseases.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

TAKEDA, DEBT IN MIND, OFFLOADS 18 DRUGS IN ASIA PACIFIC TO CELLTRION FOR $278M

Fiercepharma | June 11, 2020

news image

Takeda has earmarked another chunk of business for divestment to help it pay down debt. The Japanese pharma is offloading 18 over-the-counter and prescription drugs marketed in the Asia-Pacific region to South Korea’s Celltrion for $278 million, it said on Thursday. The portfolio generated sales of about $140 million in the fiscal year ended in March 2019, mainly driven by DPP-4 diabetes drug Nesina and hypertension med Edarbi, Takeda said. It will continue to manufacture the products and ...

Read More

GLOBAL OXYMETAZOLINE MARKET 2020 – COMPLEX PHARMACEUTICAL, ALLERGAN, ALTAIRE PHARMACEUTICALS, HEALTH LIFE OF USA

bccourier | April 16, 2020

news image

Global Oxymetazoline Market research report delivers the analysis of the market outlook, framework, and socio-economic impacts. This report tries to covers the authenticate information of the market size, share, product footprint, revenue, and progress rate. All this information driven by primary and secondary researches, with reliable and authentic projections regarding the technical jargon. This study assesses the current landscape of the ever-evolving business sector and the present and futur...

Read More

PHARMACY MARKET

VIRPAX ANNOUNCES MMS019 MANUFACTURING AND SUPPLY AGREEMENT

Virpax Pharmaceuticals | August 27, 2021

news image

Virpax® Pharmaceuticals, Inc., a company specializing in developing product candidates for pain management, CNS and anti-viral indications, today announced that it has entered into a commercial manufacturing and supply agreement with Seqens, an integrated global leader in pharmaceutical solutions with 24 manufacturing sites worldwide and seven research and development facilities throughout the U.S. and Europe. The agreement with Seqens provides for both the supply material for...

Read More

BUSINESS INSIGHTS

ASYMCHEM AND LANOVA MEDICINES ENTER INTO PARTNERSHIP AGREEMENT, EXPANDING BIOLOGICAL CAPABILITIES

Asymchem | September 17, 2021

news image

Asymchem today announced a strategic partnership agreement to provide LaNova Medicines with one-stop services such as small molecule drugs, ADC project CMCs, R&D, production and IND China-US declaration. The collaboration between Asymchem and LaNova will include small molecule drugs, monoclonal antibodies, double antibodies, ADC projects and potentially other R&D and production initiatives. This partnership will take full advantage of Asymchem's recently co...

Read More
news image

TAKEDA, DEBT IN MIND, OFFLOADS 18 DRUGS IN ASIA PACIFIC TO CELLTRION FOR $278M

Fiercepharma | June 11, 2020

Takeda has earmarked another chunk of business for divestment to help it pay down debt. The Japanese pharma is offloading 18 over-the-counter and prescription drugs marketed in the Asia-Pacific region to South Korea’s Celltrion for $278 million, it said on Thursday. The portfolio generated sales of about $140 million in the fiscal year ended in March 2019, mainly driven by DPP-4 diabetes drug Nesina and hypertension med Edarbi, Takeda said. It will continue to manufacture the products and ...

Read More
news image

GLOBAL OXYMETAZOLINE MARKET 2020 – COMPLEX PHARMACEUTICAL, ALLERGAN, ALTAIRE PHARMACEUTICALS, HEALTH LIFE OF USA

bccourier | April 16, 2020

Global Oxymetazoline Market research report delivers the analysis of the market outlook, framework, and socio-economic impacts. This report tries to covers the authenticate information of the market size, share, product footprint, revenue, and progress rate. All this information driven by primary and secondary researches, with reliable and authentic projections regarding the technical jargon. This study assesses the current landscape of the ever-evolving business sector and the present and futur...

Read More
news image

PHARMACY MARKET

VIRPAX ANNOUNCES MMS019 MANUFACTURING AND SUPPLY AGREEMENT

Virpax Pharmaceuticals | August 27, 2021

Virpax® Pharmaceuticals, Inc., a company specializing in developing product candidates for pain management, CNS and anti-viral indications, today announced that it has entered into a commercial manufacturing and supply agreement with Seqens, an integrated global leader in pharmaceutical solutions with 24 manufacturing sites worldwide and seven research and development facilities throughout the U.S. and Europe. The agreement with Seqens provides for both the supply material for...

Read More
news image

BUSINESS INSIGHTS

ASYMCHEM AND LANOVA MEDICINES ENTER INTO PARTNERSHIP AGREEMENT, EXPANDING BIOLOGICAL CAPABILITIES

Asymchem | September 17, 2021

Asymchem today announced a strategic partnership agreement to provide LaNova Medicines with one-stop services such as small molecule drugs, ADC project CMCs, R&D, production and IND China-US declaration. The collaboration between Asymchem and LaNova will include small molecule drugs, monoclonal antibodies, double antibodies, ADC projects and potentially other R&D and production initiatives. This partnership will take full advantage of Asymchem's recently co...

Read More

Resources

resource image

PHARMA TECH

Smart Pharmacovigilance

infographic

resource image

PHARMACY MARKET

A pharma outsourcing mission

Article

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us